Clinical Trial Search

Primary: Area Under the Concentration-time Curve of BI 730357 Over the Time Interval From 0 to Infinity (Dose Normalized). — NA; NA mmol*h/L/kg

Primary: Standard Deviation of Lateral Position (SDLP) — 25.490; 37.849; 33.086 cm

Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL

Primary: Plasma CT1812 Concentration at 96 Hours Timepoint — 0.0000707 μg/mL

Primary: Immune Response — 132.7; 192.8 Total number of expanded clones

Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 7; 5; 5; 7 Participants

Primary: Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 150.65; 148.34 hours…

Primary: Area Under the Concentration-time Curve of Caffeine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity, Caffeine) — 84569.29; 94764.64 hours…

Primary: Participation — 80 Participants

Primary: Area Under the Concentration-time Curve of BI 730357 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5870.79; 5197.06; 19970.22…

Primary: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin) — 1460.83; 1434.81 hour *…

Primary: Photosensitivity Index at 24 Hours Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure) — 0.93; 1.01; 1.00; 1.04…

Primary: Maximum Observed Concentration (Cmax) of PF-07321332 — 4678; 5546 ng/mL — p=0.05

Primary: Number of Participants With Drug-related Adverse Events — 0; 0; 0; 0 Participants

Primary: Area Under the Concentration-time Curve of the BI 730357 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 43239.08; 6657.49…